C ritical limb ischemia (CLI) is a condition that represents the most advanced form of peripheral artery disease (PAD). Incidences have increased for the years because of an aging society as well as an increase in patients with risk factors for atherosclerosis, especially diabetes mellitus. Accordingly, management and prevention of this condition are pressing issues from the perspectives of both medical cost and public health. 1, 2 Patients who have CLI typically present with rest pain and ischemic ulcers or gangrene. They have a poor prognosis, with a high mortality rate (19%-54% at 1 year) [3] [4] [5] and high amputation rate (≥25% at 6 months after failure of primary revascularization). In clinical settings, bypass surgery (BS) has been the gold standard for revascularization in CLI patients because the culprit lesions are commonly occlusive and multilevel or multisegment and BS has been shown to be efficacious and durable. However, in reality, in many cases, BS is not applied to patients with CLI because of concomitant diseases and advanced age, which are common in CLI patients and make endovascular treatment (EVT) the preferable treatment.
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The Bypass Versus Angioplasty in Severe Ischemia of the Leg (BASIL) trial is the only prospective randomized trial to compare EVT with BS for CLI. This study provided the most convincing evidence for selecting the CLI revascularization procedure, and the authors concluded that a revascularization strategy should be determined by usable autologous veins and predicted life expectancy. [6] [7] [8] However, even this well-designed trial has several critical limitations that make the findings less applicable to daily practice. Although this study plays an important role in decisions for revascularization strategies, the study population and procedural results do not reflect recent clinical practice and direct adaptation of BASIL results are clinically questioned. 9 Due to recent development of dedicated devices and an accumulation of experience, EVT outcomes have considerably improved and EVT is becoming an alternative first-line option for the treatment of CLI and intermittent claudication. [10] [11] [12] [13] [14] [15] Despite this major paradigm shift, EVT outcomes have not been systematically compared with those of BS in welldesigned studies. Most studies have been retrospective singlecenter trials involving patients treated for long periods of time, leading to heterogeneity in intervention indications, location of diseased vessels, clinical characteristics, procedural end points, and EVT techniques.
To begin to address some of these issues, we initiated the Endovascular Treatment for Infrainguinal Vessel, ie, the OLIVE Registry, a prospective multicenter study with 12-month follow-up, in patients with CLI to evaluate substantial outcomes of EVT in Japanese CLI patients with infrainguinal disease (including those with end-stage renal disease [ESRD]) treated in real-world settings. In this study, the wound healing process also was independently reviewed by a wound core laboratory.
Methods

Study Design
CLI patients undergoing EVT for treatment of infrainguinal disease were consecutively enrolled at 19 centers in Japan (Appendix A in the online-only Data Supplement). At 1, 3, 6, and 12 months after EVT, outcomes were assessed with regard to survival, major amputation, symptoms and signs of ischemia, quality of life (QOL), and adverse events. All participating patients gave informed consent before enrollment and the study protocol was approved by the Institutional Review Board of each participating center. This study was registered as UMIN000002830 (OLIVE Registry) in the University Hospital Medical Information Network Clinical Trials Registry (http://www.umin.ac.jp/ctr/), which is a public trial registry approved by the International Committee of Medical Journal Editors. The study organization is described in the Appendix B in the online-only Data Supplement.
Subjects
Three hundred patients were planned to be enrolled during the period from December 2009 to July 2011, and followed-up to July 2012.
To be enrolled in the study, patients had to have de novo CLI (Rutherford classification 4-6) 16,17 caused by infrainguinal disease and had to be available for follow-up for 1 year after EVT. Exclusion criteria were the following: 1) previous major amputation; 2) life expectancy of <1 year; 3) dementia that precluded assessment of QOL; 4) difficulty in achieving follow-up after EVT; 5) unsalvageable limb defined as extensive ischemic ulceration or gangrene beyond the transmetatarsal level that would eventually require major amputation after EVT; 6) concurrent iliac artery disease; and 7) CLI attributable to acute arterial occlusion or attributable to nonatherosclerotic or inflammatory diseases. The CLI definition parameters are described in the online-only Data Supplement on page 1.
Endovascular Intervention
EVT strategy selection was left to the discretion of the treating physicians at each center. Superficial femoral lesions were treated with provisional nitinol stenting, whereas popliteal and below-the-knee (BTK) lesions were treated with balloon angioplasty without stenting. Long balloons (100-120 mm) were used to treat the BTK lesions, which were commonly extensive and diffuse. Each vessel was sized visually and stenosis or occlusion was dilated by inflating the selected balloon for 3 minutes at nominal pressure.
Follow-up Protocol
At 1, 3, 6, and 12 months after EVT, each patient was assessed by symptoms, ankle brachial index, skin perfusion pressure (SPP)
WHAT IS KNOWN
• The optimal treatment of critical limb ischemia (CLI) is revascularization.
• Bypass surgery is an efficacious and durable revascularization strategy, but it is not suitable for all patients.
• Endovascular treatment (EVT) is an alternative firstline option for the treatment of CLI, but existing data on this therapy are limited by predominantly retrospective single-center studies with long recruitment periods.
WHAT THE STUDY ADDS
• EVT outcomes in Japanese CLI patients with infrainguinal disease were elucidated in a prospective, multicenter, all-comers registry.
• Reintervention rates were high but wound healing was achieved within ≈3 months in half the patients and EVT overall achieved favorable outcomes. monitoring/testing (Sensilase PAD 3000; Väsamed, Eden Prairie, MN), and duplex ultrasound parameters. Reintervention was conducted only when indicated clinically by breakdown or delayed healing of the primary ulcer.
Ulcer Assessment by Wound Core Laboratory
Before treatment, patients with ulcers or gangrene had their lesions photographed from 3 angles with a control-colored measuring tape applied near the wound. Ulcers were photographed from the same angles at each subsequent outpatient follow-up to monitor the healing process. Pictures were routinely taken before and after endovascular procedure, and at 1, 3, 6, and 12 months after EVT. All photographs were reviewed by an independent plastic surgeon blinded to the baseline characteristics of the patients and the EVT strategies used to treat them. The primary examination end point was the time required for 100% epithelialization of the reference wound, which was completely closed either by surgical intervention (skin graft, flap, and suture) or by secondary intention. The assessor also determined the presence or absence of infection.
QOL Assessment
QOL evaluation was performed using a previously validated method, EuroQOL, in which the levels of a patient's mobility, self-care, usual activity, pain or discomfort, and anxiety or depression, as well as the health state were self-rated by using a designated questionnaire. 6 Assessment of QOL was performed before EVT, as well as at 1, 3, 6, and 12 months after EVT.
Primary and Secondary End Points
The primary end point of this study was amputation-free survival (AFS) at 12 months. Secondary end points included the following: 1) procedural success and complication rates; 2) 30-day rates of major adverse cardiovascular events (myocardial infarction, stroke or death, and any cause of death), major adverse limb events (MALE), and major amputation (major amputation defined as above-ankle amputation) as safety end points; 3) 12-month rates of freedom from MALE, defined as major amputation or major reintervention including surgical procedure, survival, limb salvage, freedom from reintervention (surgical or EVT), and freedom from major adverse events (myocardial infarction, stroke, any cause of death or above-ankle amputation of the index limb) as end points; 4) time to ulcer healing; and 5) changes in QOL score. The end point definitions are described in the online-only Data Supplement on page 2.
Statistical Analysis
Continuous data were expressed as mean ± standard deviation (SD) or medians with the first and third quartiles (Q1-Q3) as appropriate and categorical data were expressed as numbers with percentages. Single Cox proportional hazard regression analysis or a log-rank test was performed to examine multiple variables individually for a possible association with AFS, time to MALE, and time to wound healing. Next, a multivariable Cox proportional hazard regression analysis was performed to determine which factors were significantly associated with each time-to-event outcome. Each variable with a significant association (P<0.25) and additional variables that were not significant but had potential clinical importance were introduced into the stepwise multivariable proportional hazard regression model to identify the factors as independent predictors of each time-to-event outcome. For the stepwise algorithm, we set P=0. 25 for entry into the model and P=0.20 to remain in the model. The hazard ratio (HR) and its 95% confidence interval for each possible risk factor were also calculated. Furthermore, the Kaplan-Meier curves were estimated by groups categorized by the number of risk factors and compared by log-rank test. The time courses of EuroQoL scores were analyzed, using generalized estimating equations, in which the time was included into the model as categorical. Two-sided P<0.05 was considered to be statistically significant. All statistical analyses were performed with SAS 9.3 for Window (SAS Institute, Cary, NC).
Results
Study Participants
During the study period, 149 CLI patients were treated with surgical bypass therapy by a vascular surgeon, and the overall number of CLI patients treated with only EVT was 760 patients. A total of 314 patients were enrolled. Two were excluded because of protocol violations (concomitant iliac artery disease), leaving 312 evaluable patients. Among these, 22 were lost to follow-up, and the remaining 290 (93%) completed 1 year of follow-up. Median follow-up time was 358.0 days (190.0-371.0). Fifty-nine died before 1 year. Among those who died, 39% (23/59) of deaths were attributed to infectious disease, and 20% (12/59) died because of cardiac reasons. The overall participant flow is shown in Figure 1 . Table 1 summarizes the baseline characteristics of the patients and their ischemic limbs. The patients had a mean age of 73±10 years. The most prevalent comorbidities were diabetes mellitus (71%; 223/312) and ESRD requiring dialysis (52%; 163/312), followed by coronary artery disease (46%; 143/312) and cerebrovascular disease (21%; 66/312). Previous treatment or hospitalization for heart failure was documented in 26% (80/312) of the patients. Regarding limb condition, 48% (150/312) presented with history of intermittent claudication, and tissue loss was observed in 88% (274/312). According to the independent assessor, 15% (48/312) of patients had infected ulcers or gangrene. The definition of risk parameters is defined in the online-only Data Supplement, Supplemental Methods on page 1. 
Patient Characteristics
Lesion Characteristics and Interventions
Initial Results of Endovascular Treatment
The mean procedure time was 111.1±62.2 minutes. Table 3 shows the initial results of endovascular treatment. After revascularization of culprit lesions, 1 straight line flow to the foot was obtained in 93% of patients (290/312). Complications occurred in 4% of patients (12/312), including vascular perforation (n=5), hemorrhage at the puncture site (n=4), vascular dissection (n=2), and vascular rupture (n=1). Figure 2 and Supplementary Figures I and II show the 12-month AFS, freedom from major amputation, and overall survival after primary EVT. The AFS rate was 81% at 6 months and 74% at 12 months. The result of single regression analysis for AFS is depicted in Supplementary Table I . As shown in Table  4 , multivariable analysis of AFS correlates showed that body mass index (BMI) <18.5 (HR, 2.22; P=0.008), heart failure Bed-ridden 74 (25) ABI indicates ankle brachial index; ADL, activities of daily living; BMI, body mass index; BNP brain natriuretic peptide; CRP, C-reactive protein; number of depressors, number of antihypertensive drugs required to control blood pressure; and SPP, skin perfusion pressure.
Primary End Point
*Hemoglobin <13 g/dL for men and <11 g/dL for women (median). †Median value [25%-75%]. 
Secondary End Points
Safety End Points
The 30-day major adverse cardiovascular event, MALE, and major amputation rates were 2.2% (7/312), 1.9% (6/312), and 1.3% (4/312), respectively. Figure 3 shows 12-month freedom from MALE after primary EVT. The freedom from MALE rate was 91% at 6 months and 88% at 12 months. The result of single regression analysis for MALE is depicted in Supplementary Table II . As shown in Table 4 , multivariable analysis of factors associated with MALE revealed that hemodialysis (HR, 1.98; P=0.005), heart failure (HR, 1.69; P=0.02), and Rutherford classification 6 (HR, 2.25; P=0.002) were independently associated with a worse prognosis. Twelve-month freedom from MALE stratified by the number of risk factors also was shown in Figure  3 . Freedom from MALE decreased as the number of risk factors increased. The 12-month rates were as follows: low (0), 96%; moderate (1), 88%; and high (2-3), 78% (P<0.001). The estimated 12-month major adverse cardiovascular event and major adverse event rates were 17% and 27%, respectively. Freedom from major adverse event is shown in Supplementary Figure III . Figure 4 shows Kaplan-Meier estimates of the time to healing for ischemic ulcers after infrainguinal revascularization. The ulcer healing rates (standard error) were 25% at 42 days, 50% at 98 days, and 75% at 195 days. The median time required for complete ulcer healing was 97 days, and 34% of patients underwent reintervention (BS, 2.6%; repeat EVT, 31.7%) to achieve freedom from ischemic symptoms (Supplementary Figures  IV and V ). An average of 1.4±0.7 reattempts were performed after the first procedure during the course of 133±90.7 days The single regression analysis results for failure to achieve wound healing is depicted in the Supplementary Table III . As shown in Table 4 , multivariable analysis of factors associated with failure to achieve healing showed that BMI<18.5 (HR, 0.54; P=0.03) and wound infection (HR, 0.60; P=0.04) were significant risk factors for delayed healing of ischemic ulcers. Time to wound healing based on risk factors also is shown in Figure 5 shows a comparison of EuroQOL scores before and after EVT. The EuroQOL score improved at 1 months after EVT and this improvement was maintained at 12 months. Figure 2 . Amputation-free survival (AFS) after endovascular treatment (EVT) rates for 312 patients with critical limb ischemia (CLI) attributable to infrainguinal lesions and risk stratification for AFS based on multivariable Cox proportional hazards regression analysis. AFS rates were 86±2%, 81±2%, 77±3%, and 74±3% at 3, 6, 9, and 12 months, respectively. Patients were assigned to 1 of 3 risk groups based on the number of risk factors where 0 risk factors was defined as a "low" risk group, 1 as "moderate", and 2-3 as "high", with the risk factors being comprised of BMI<18.5, heart failure, and wound infection. AFS was lower in the higher risk groups (12-month rates: low, 85%; moderate, 65%; high, 48%; P<0.001). Freedom from major adverse limb events (MALE) after endovascular therapy (EVT) for 312 patients with critical limb ischemia (CLI) attributable to infrainguinal lesions and risk stratification for freedom from MALE based on multivariable Cox proportional hazards regression analysis. Freedom from MALE was 93±2%, 91±2%, 90±2%, and 88±2% at 3, 6, 9, and 12 months, respectively. Patients were assigned to one of 3 risk groups based on the number of risk factors where 0 risk factors was defined as a "low" risk group, 1 as "moderate", and 2-3 as "high", with the risk factors being comprised of hemodialysis, heart failure and Rutherford classification 6. MALE was lower in the higher risk groups (12-month rates: low, 96%; moderate, 88%; high, 78%). . Proportion of wound healing in 274 chronic limb ischemia (CLI) patients with tissue loss (ulceration or gangrene or both) after endovascular treatment and risk stratification for wound healing based on multivariable Cox proportional hazard regression analysis. The proportion of not-healed patients was 54±3%, 29±3%, 18±3%, and 14±3% at 3, 6, 9, and 12 months, respectively. Median value was 97±10 days. Patients were assigned to 1 of 3 risk groups based on the number of risk factors where 0 risk factors was defined as a "low" risk group, 1 as "moderate", and 2 as "high", with the risk factors being comprised of BMI<18.5 and wound infection. Patients in the low-risk and moderate-risk groups achieved earlier wound healing than those in the high-risk group. The median time to complete ulcer healing was as follows: low, 87 days; moderate, 106 days; and high, 128 days.
Efficacy End Points
Time to Ulcer Healing
Changes in QOL
Discussion
What Difference Does This Study Make?
Previous studies have suggested favorable EVT outcomes for CLI, 10-13 but at the same time they revealed contradictory results for the relative benefit compared with BS. A metaanalysis of studies comparing EVT with BS for infrapopliteal disease showed that EVT was inferior to BS for patency but comparable for freedom from major amputation and survival. 18, 19 In contrast, the final analysis of the BASIL trial showed better long-term AFS outcomes after BS on autologous veins compared with EVT. 7, 8 Possible explanations for these inconsistencies include methodological differences between studies, including intervention indications, limb selection, EVT strategies, and end point and follow-up period definitions. 9 Because procedures and guidelines by necessity change over time, retrospective analyses, especially those conducted for long periods, will contain inherent clinical inconsistencies. Therefore, it is impossible to draw a definite conclusion from previous reports as to what extent EVT techniques provide benefit for differing levels of CLI severity. The present OLIVE Registry study is a prospective multicenter study that recruited subjects for a relatively short period (20 months), thereby capturing a more consistent clinical environment. Additionally, the wound healing process was assessed by an independent plastic surgeon in a wound core laboratory. The limitations of the BASIL trial include the following: 1) it enrolled patients with severe limb ischemia including those with an ankle pressure ≥50 mm Hg; 2) it excluded patients with ESRD; 3) it included relatively few patients with isolated BTK lesions, the most challenging form of CLI; 4) it did not report the anatomic severity of lesions; and 5) it revealed a high primary procedural failure rate of 20% and investigated a limited range of EVT strategies (balloon angioplasty only). To overcome these limitations, the present study started with:
1. Only enrolled patients with CLI 2. Enrolled ESRD (either on dialysis or predialysis) patients 3. Included 40% of patients with isolated BTK lesions, which present the poorest prognosis 4. Graded individual lesions anatomically 5. Achieved a high primary procedural success rate of 93%; femoropopliteal lesions were treated with nitinol stents Several recent studies have proposed objective performance goals (OPGs) for use in the evaluation of EVT strategies for CLI. Conte et al 20 estimated OPGs for EVT efficacy and safety using BS as the standard treatment modality for comparison by analyzing data from 838 patients in the following 3 randomized controlled studies: 1) the PREVENT III study; 2) the BASIL trial; and 3) the CIRCULASE trial. The reported OPGs for efficacy of catheter-based revascularization were AFS, freedom from MALE, limb salvage, and survival, with rates of 71%, 71%, 84%, and 80%, respectively. In the OLIVE Registry study, we obtained comparable data for 12-month AFS (74%), freedom from MALE (71%), limb salvage (84%), survival (80%), and freedom from reintervention or major amputation (58%). The outcome of EVT in this registry was unexpectedly favorable in view of the fact that the majority of subjects had ESRD and were on dialysis, which compromises EVT outcomes. Considering that the results of previous clinical trials have not reflected the most current EVT technology for CLI (such as nitinol stenting of the femoral artery and long balloons for BTK lesions), the favorable outcome of EVT in this registry study possibly may be a reflection of the benefit of recent EVT devices, which may have offset the negative influence of ESRD. The success rate for EVT was 93%, which is comparable with results from recent studies. In this study, the mean postprocedural SPP of both the dorsalis and plantar sides was >40 mm Hg, which is comparable to the SPP necessary for ulcer healing, according to Castronuovo et al. 21 Thus, it seems reasonable to conclude that adequate blood flow for ischemic ulcer healing has been achieved by EVT in this study. Recently, Zhan et al 22 reported that endovascular intervention is as effective as BS with regard to initial improvement of hemodynamics when performed on appropriate patient populations, and the results of the current study support this conclusion. Although the usefulness of tissue perfusion assessment after EVT in relation to ulcer healing has not been sufficiently evaluated, the present study suggests the value of such an assessment.
Factors that are commonly associated with ulcer healing, AFS, and freedom from MALE include BMI <18.5, hemodialysis, history of heart failure, wound infection, and Rutherford classification 6. The results of this study were generally in agreement with those of previous reports. [23] [24] [25] [26] TASC II recommends that factors that can negatively affect wound healing, such as cardiac failure or poor nutritional status, should be evaluated and treated appropriately. 11 BMI <18 was a novel correlate of AFS in CLI patients. Interestingly, patients with peripheral artery disease who were obese or overweight showed a better survival rate than patients with normal weight; this has been termed the "obesity paradox." 27 The presence of heart failure negatively impacts patient prognosis without exception, including CLI patients. As chronic kidney disease progresses, the results also worsen and outcomes for patients on dialysis are very poor. 25, 26, [28] [29] [30] A metaanalysis of the results of revascularization using venous grafts revealed that the 5-year amputation-free rate for the lower limb was 67% and the survival rate was 25% in patients on dialysis. 31 Dialysis also was the most important risk factor in our study population. A number of conditions often connected to ESRD, such as anemia, malnutrition, depressed immunity, and insufficient collagen in granulation tissue, also were independent predictors of limb salvage and mortality in the present study. Regarding limb status, the presence of wound infection in the lower limb is a widely accepted factor increasing the demand for blood flow to the microvascular bed and consequently resulted in a poorer prognosis in our patients.
Diabetes is one of the major risk factors for lower limb amputation in patients with CLI. 23, 24 A high incidence of infrapopliteal lesions, 32 neurological disorders, increased susceptibility to infection, lower limb deformity, and renal impairment are considered contributing factors in patients with diabetes. 33, 34 In fact, even when a venous graft remains patent, the risk of lower limb amputation is reported to be high in patients with diabetes. 35 However, diabetes was not an independent factor associated with wound healing and limb salvage in the present analysis, of which 71% patients who had diabetes. By means of reintervention (34%), the limb salvage rate was comparable to the OPG estimated by Conte et al. It has been reported that diabetic patients with CLI benefitted from revascularization regardless of the modality chosen, although multiple procedures may be required to obtain complete wound healing. 36 Furthermore, Schanzer et al recently developed a model to predict AFS using the PREVENT III cohort and stated that diabetes was not a predictor of AFS. 37 Taken together, it may be explained that the incorporation of tissue infection and hemodialysis into analysis attenuated the association between diabetes and mortality and the outcomes of limb, because patients with ESRD comprised >50% of the patients in this study.
Clinical Implications
The results of this study are considered to reflect recent progress of EVT in a relatively homogenous group of patients recruited for a short period and substantially serve as a helpful study in catheter-based treatment. In CLI patients who undergo EVT for infrainguinal lesions, especially infrapopliteal lesions, an assessment of tissue perfusion based on SPP may serve as an index for procedural success or failure and postprocedural management. Furthermore, the end points determined in this study may provide useful data for the clinical management of CLI in the future.
Limitations
This study was not an RCT of EVT compared with either BS or medical therapy. In contrast with long-established procedures and well-known outcomes of BS, the rapid evolution of EVT for the past decade has resulted in increased disparity in results among centers, as reflected in our registry study. This discrepancy includes not only EVT treatment strategy and procedure techniques, but also the management of wound care and concomitant medication use. Further investigation will be needed to establish novel techniques for revascularization and end points, including EVT quality, especially the impact of the angiosome concept 38 and wound blush as an angiographic end point. 39 Additionally, SPP was used to assess the level of ischemia improvement after EVT instead of the more widely used TcPO 2 and ankle brachial index because this was not reflected in vessel calcification leading to assess precisely microcirculation without false-negative evaluation by ankle brachial index. 40 The clinical efficiency of SPP also warrants further investigation. A follow-up study of the patients in this study should be considered to assess the longer-term outcome.
Conclusions
Despite a high reintervention rate, especially among BTK patients, EVT achieved favorable outcomes in Japanese patients with CLI from infrainguinal lesions.
